PMID- 26969202
OWN - NLM
STAT- MEDLINE
DCOM- 20170104
LR  - 20170105
IS  - 2059-2310 (Electronic)
IS  - 2059-2302 (Linking)
VI  - 87
IP  - 5
DP  - 2016 May
TI  - Conflicting HLA assignment by three different typing methods due to the apparent 
      loss of heterozygosity in the MHC region.
PG  - 350-5
LID - 10.1111/tan.12770 [doi]
AB  - Loss of heterozygosity (LOH) has been reported to cause false human leukocyte 
      antigen (HLA) homozygous typing results in pre-transplant patients suffering from 
      haematological malignancies, who in fact are HLA heterozygous. This poses a 
      challenge for histocompatibility testing, as a stem cell graft from a genuinely 
      HLA homozygous donor to a mistyped patient may lead to acute life-threatening 
      graft-vs-host disease. LOH in the HLA region on chromosome 6 is known to be quite 
      common in solid tumours, helping malignant cells to escape T-cell surveillance, 
      but the incidence in haematological malignancies is less well known and the 
      estimates vary. Here we report LOH in the HLA region of five patients with 
      haematological malignancy. We found considerable differences in sensitivity 
      between the three different HLA typing methods used in our laboratory: SSP was 
      clearly the most sensitive method for detecting the lost haplotype, followed by 
      rSSO, while SBT was the least sensitive technique. A subsequent, retrospective 
      genotyping of 65 HLA homozygous haematological patients by SSP method showed no 
      mistyped LOH cases in our laboratory in the past 10 years. The frequency of HLA 
      homozygosity was found to be similar between haematological patients and control 
      groups. It is important for an HLA laboratory to be aware of the differences in 
      various HLA typing techniques' sensitivity for detecting an under-represented 
      haplotype between HLA typing techniques when genotyping patients with 
      haematological diseases. It is advisable for HLA laboratories to have at least 
      two different methods with different sensitivities in their repertoire to be able 
      to retype samples when a false homozygous result is suspected.
CI  - (c) 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.
FAU - Linjama, T
AU  - Linjama T
AD  - Department of Research and Development, Finnish Red Cross Blood Service, 
      Helsinki, Finland.
FAU - Impola, U
AU  - Impola U
AD  - Department of Research and Development, Finnish Red Cross Blood Service, 
      Helsinki, Finland.
FAU - Niittyvuopio, R
AU  - Niittyvuopio R
AD  - Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki University 
      Central Hospital, Helsinki, Finland.
FAU - Kuittinen, O
AU  - Kuittinen O
AD  - Department of Oncology, Oulu University Hospital, Oulu, Finland.
FAU - Kaare, A
AU  - Kaare A
AD  - Department of Haematology and Bone Marrow Transplantation, Tarto University 
      Hospital, Tarto, Estonia.
FAU - Rimpilainen, J
AU  - Rimpilainen J
AD  - Department of Internal Medicine, Tampere University Hospital, Tampere, Finland.
FAU - Volin, L
AU  - Volin L
AD  - Comprehensive Cancer Center, Stem Cell Transplantation Unit, Helsinki University 
      Central Hospital, Helsinki, Finland.
FAU - Perasaari, J
AU  - Perasaari J
AD  - Department of Research and Development, Finnish Red Cross Blood Service, 
      Helsinki, Finland.
FAU - Jaatinen, T
AU  - Jaatinen T
AD  - Department of Research and Development, Finnish Red Cross Blood Service, 
      Helsinki, Finland.
FAU - Lauronen, J
AU  - Lauronen J
AD  - Department of Research and Development, Finnish Red Cross Blood Service, 
      Helsinki, Finland.
FAU - Saarinen, T
AU  - Saarinen T
AD  - Department of Research and Development, Finnish Red Cross Blood Service, 
      Helsinki, Finland.
FAU - Juvonen, E
AU  - Juvonen E
AD  - Department of Research and Development, Finnish Red Cross Blood Service, 
      Helsinki, Finland.
FAU - Partanen, J
AU  - Partanen J
AD  - Department of Research and Development, Finnish Red Cross Blood Service, 
      Helsinki, Finland.
FAU - Koskela, S
AU  - Koskela S
AD  - Department of Research and Development, Finnish Red Cross Blood Service, 
      Helsinki, Finland.
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
DEP - 20160310
PL  - England
TA  - HLA
JT  - HLA
JID - 101675570
RN  - 0 (HLA Antigens)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Case-Control Studies
MH  - HLA Antigens/*metabolism
MH  - Haplotypes/genetics
MH  - Histocompatibility Testing/*methods
MH  - Homozygote
MH  - Humans
MH  - Loss of Heterozygosity/*genetics
MH  - *Major Histocompatibility Complex
MH  - Middle Aged
OTO - NOTNLM
OT  - HLA typing
OT  - haematological malignancy
OT  - loss of heterozygosity
OT  - transplantation
EDAT- 2016/03/13 06:00
MHDA- 2017/01/05 06:00
CRDT- 2016/03/13 06:00
PHST- 2015/11/25 00:00 [received]
PHST- 2016/01/26 00:00 [revised]
PHST- 2016/02/17 00:00 [accepted]
PHST- 2016/03/13 06:00 [entrez]
PHST- 2016/03/13 06:00 [pubmed]
PHST- 2017/01/05 06:00 [medline]
AID - 10.1111/tan.12770 [doi]
PST - ppublish
SO  - HLA. 2016 May;87(5):350-5. doi: 10.1111/tan.12770. Epub 2016 Mar 10.